265 related articles for article (PubMed ID: 12223434)
1. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
[TBL] [Abstract][Full Text] [Related]
3. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
4. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
Kamataki T; Fujieda M; Kiyotani K; Iwano S; Kunitoh H
Biochem Biophys Res Commun; 2005 Dec; 338(1):306-10. PubMed ID: 16176798
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.
Ruwali M; Pant MC; Shah PP; Mishra BN; Parmar D
Mutat Res; 2009 Oct; 669(1-2):36-41. PubMed ID: 19406142
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies.
Liu T; Xie CB; Ma WJ; Chen WQ
Environ Mol Mutagen; 2013 Mar; 54(2):133-40. PubMed ID: 23203414
[TBL] [Abstract][Full Text] [Related]
8. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.
Loriot MA; Rebuissou S; Oscarson M; Cenée S; Miyamoto M; Ariyoshi N; Kamataki T; Hémon D; Beaune P; Stücker I
Pharmacogenetics; 2001 Feb; 11(1):39-44. PubMed ID: 11207029
[TBL] [Abstract][Full Text] [Related]
10. CYP2A6 gene deletion reduces susceptibility to lung cancer.
Miyamoto M; Umetsu Y; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Nemoto N; Sato K; Ariyoshi N; Kamataki T
Biochem Biophys Res Commun; 1999 Aug; 261(3):658-60. PubMed ID: 10441482
[TBL] [Abstract][Full Text] [Related]
11. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms.
Minematsu N; Nakamura H; Furuuchi M; Nakajima T; Takahashi S; Tateno H; Ishizaka A
Eur Respir J; 2006 Feb; 27(2):289-92. PubMed ID: 16452582
[TBL] [Abstract][Full Text] [Related]
12. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
O'Loughlin J; Paradis G; Kim W; DiFranza J; Meshefedjian G; McMillan-Davey E; Wong S; Hanley J; Tyndale RF
Tob Control; 2004 Dec; 13(4):422-8. PubMed ID: 15564629
[TBL] [Abstract][Full Text] [Related]
13. An association of CYP2A6 genotype and smoking topography.
Strasser AA; Malaiyandi V; Hoffmann E; Tyndale RF; Lerman C
Nicotine Tob Res; 2007 Apr; 9(4):511-8. PubMed ID: 17454707
[TBL] [Abstract][Full Text] [Related]
14. [How I was enticed into molecular toxicology].
Kamataki T
Yakugaku Zasshi; 2006 Dec; 126(12):1309-18. PubMed ID: 17139156
[TBL] [Abstract][Full Text] [Related]
15. [Researches on the polymorphism of cytochrome P450 2A6].
Tong Z; ZhuGe J; Yu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):424-7. PubMed ID: 12362322
[TBL] [Abstract][Full Text] [Related]
16. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.
Yuan JM; Nelson HH; Carmella SG; Wang R; Kuriger-Laber J; Jin A; Adams-Haduch J; Hecht SS; Koh WP; Murphy SE
Carcinogenesis; 2017 Apr; 38(4):411-418. PubMed ID: 28182203
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults.
Ando M; Hamajima N; Ariyoshi N; Kamataki T; Matsuo K; Ohno Y
J Epidemiol; 2003 May; 13(3):176-81. PubMed ID: 12749606
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.
Islam MS; Ahmed MU; Sayeed MS; Maruf AA; Mostofa AG; Hussain SM; Kabir Y; Daly AK; Hasnat A
Clin Chim Acta; 2013 Feb; 416():11-9. PubMed ID: 23178447
[TBL] [Abstract][Full Text] [Related]
19. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.
Liu YL; Xu Y; Li F; Chen H; Guo SL
Tumour Biol; 2013 Oct; 34(5):2651-7. PubMed ID: 23649654
[TBL] [Abstract][Full Text] [Related]
20. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
